Rheumatoid Arthritis

Biosimilar Hyrimoz® (adalimumab) approved

Holzkirchen, July 27, 2018 – Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the European Commission (EC) granted marketing authorization to biosimilar Hyrimoz® […]